Dr. Levy On Egfr Tkis In Lung Cancer

Dr. Levy on EGFR TKIs in Lung Cancer

EGFR TKIs for Upfront Treatment of NSCLC

Dr. Levy Discusses the FLAURA Study in Lung Cancer

Dr. Levy on the Treatment of T790M-Mutant Lung Cancer

2020 CBPD LEVY - CASE 1 - Timing and Treatment for 48 YO Male with EGFR NSCLC High PDL1

GRACE - Global Resource for Advancing Cancer Education

Managing Resistance to EGFR TKIs in NSCLC

EGFR TKIs as Adjuvant Therapy in NSCLC

Dr. Levy on Therapy for Rapidly Progressing NSCLC

Dr. Levy on the Role of Chemotherapy in the Treatment of Lung Cancer

Targeted Oncology

Dr. Levy on First-Line Treatment for Nondriver NSCLC

Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

Exploring neoadjuvant EGFR-TKIs in lung cancer

Dr. Levy on Treatments for Oncogenic-Driven NSCLC

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

Benjamin Levy on Advances in Diagnosing Lung Cancer

Dr. Levy on Investigational Biomarkers of Response to Immunotherapy in NSCLC

Drs. Johnson, Levy, & Yu discuss the latest Lung Cancer updates from #WCLC21: https://bit.ly/3gOriYo

PeerView Oncology

Dr. Heather Wakelee on What to Do When Resistance to EGFR TKIs Emerges

EGFR TKI Sequencing

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer